Presence of Genes Encoding Panton-Valentine Leukocidin Is Not the Primary Determinant of Outcome in Patients with Hospital-Acquired Pneumonia Due to Staphylococcus aureus

The impact of Panton-Valentine leukocidin (PVL) on the outcome inStaphylococcus aureus pneumonia is controversial. We genotypedS. aureus isolates from patients with hospital-acquired pneumonia (HAP) enrolled in two registrational multinational clinical trials for the genetic elements carryingpvl and 30 other virulence genes. A total of 287 isolates (173 methicillin-resistantS. aureus [MRSA] and 114 methicillin-susceptibleS. aureus [MSSA] isolates) from patients from 127 centers in 34 countries for whom clinical outcomes of cure or failure were available underwent genotyping. Of these,pvl was detected by PCR and its product confirmed in 23 isolates (8.0%) (MRSA, 18/173 isolates [10.4%]; MSSA, 5/114 isolates [4.4%]). The presence ofpvl was not associated with a higher risk for clinical failure (4/23 [17.4%] versus 48/264 [18.2%];P = 1.00) or mortality. These findings persisted after adjustment for multiple potential confounding variables. No significant associations between clinical outcome and (i) presence of any of the 30 other virulence genes tested, (ii) presence of specific bacterial clone, (iii) levels of alpha-hemolysin, or (iv) delta-hemolysin production were identified. This study suggests that neitherpvl presence norin vitro level of alpha-hemolysin production is the primary determinant of outcome among patients with HAP caused byS. aureus .